Peter Ruile has 25 years of experience and a deal track record of ~ € 2 bn. Prior to joining advanceCor GmbH he was VP BD&L at Cardior and was crucial for the M&A by Novo Nordisk for up to € 1 bn in 2024. Before Cardior he was Operations Director of GPAAD at Helmholtz Zentrum München. Earlier he was Deputy Head BD and Senior Director of Innovation Capital at MorphoSys. Prior to MorphoSys he worked as COO at Ascenion. Peter Ruile started as Assistant Managing Director of GSF and soon became Managing Director of ITN.